[Renal toxicity of high-dose methotrexate].

CONCLUSION: Sixty-one percent of patients received a glucarpidase perfusion during acute kidney injury. Despite a dramatic decrease of methotrexate serum levels, glucarpidase as compared with conservative treatment did not modify acute kidney injury stage, recovery delay, need for renal replacement therapy or the incidence of extrarenal toxicities. Net clinical benefit was not observed even after stratification according to eligibility criteria for glucarpidase use. Glucarpidase has probably no or little effects on methotrexate localized into tubular lumen or proximal tubular cells and that may account for the absence of nephroprotective effect for enzymatic treatment.
PMID: 29606256 [PubMed - in process]

Source: Nephrologie and Therapeutique - April 1, 2018 Category: Urology & Nephrology Authors: Garcia H, Leblond V, Goldwasser F, Bouscary D, Raffoux E, Boissel N, Broutin S, Joly D Tags: Nephrol Ther Source Type: research